Literature DB >> 2373120

Effects of highly overdosed indomethacin in a preterm infant with symptomatic patent ductus arteriosus.

V Schuster1, H B von Stockhausen, H W Seyberth.   

Abstract

We describe a preterm infant with severe idiopathic respiratory distress syndrome (iRDS, hyaline membrane disease) who needed artificial ventilation with high inspiratory pressure, high frequencies, 100% oxygen and developed a symptomatic patent ductus arteriosus (sPDA) in the course of the disease. The infant was given indomethacin to induce constriction of sPDA. Due to an error in drug dilution the patient received a 100-fold overdose of indomethacin. Compared to the normal study protocol side-effects such as renal failure were not observed probably due to sufficient fluid intake and good clinical condition prior to treatment and to the rapid and persistent ductal closure.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2373120     DOI: 10.1007/bf02034756

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

1.  Effect of a modified fluid therapy on renal function during indomethacin therapy for persistent ductus arteriosus.

Authors:  J U Leititis; R Burghard; N Gordjani; A Wildberg; H W Seyberth; M Brandis
Journal:  Acta Paediatr Scand       Date:  1987-09

2.  Pharmacology of the ductus arteriosus.

Authors:  R I Clyman; M A Heymann
Journal:  Pediatr Clin North Am       Date:  1981-02       Impact factor: 3.278

3.  Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus.

Authors:  H W Seyberth; G Knapp; D Wolf; H E Ulmer
Journal:  Eur J Pediatr       Date:  1983-12       Impact factor: 3.183

4.  Pharmacokinetics and clinical efficacy of indomethacin in premature infants with patent ductus arteriosus.

Authors:  M B Regazzi; R Rondanelli; E Vidale; G Chirico; G Rondini; A Chiara; A Piccolo
Journal:  Int J Clin Pharmacol Res       Date:  1984

5.  Pharmacologic closure of patent ductus arteriosus in the premature infant.

Authors:  W F Friedman; M J Hirschklau; M P Printz; P T Pitlick; S E Kirkpatrick
Journal:  N Engl J Med       Date:  1976-09-02       Impact factor: 91.245

6.  Intravenous indomethacin and changes of renal function in premature infants with patent ductus arteriosus.

Authors:  E G John; U Vasan; A R Hastreiter; R Bhat; M A Evans
Journal:  Pediatr Pharmacol (New York)       Date:  1984

7.  Prolonged indomethacin treatment in preterm infants with symptomatic patent ductus arteriosus: efficacy, drug level monitoring, and patient selection.

Authors:  A Leonhardt; V Isken; P G Kühl; H W Seyberth
Journal:  Eur J Pediatr       Date:  1987-03       Impact factor: 3.183

8.  Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus--a double-blind controlled study.

Authors:  T F Yeh; J A Luken; A Thalji; D Raval; I Carr; R S Pildes
Journal:  J Pediatr       Date:  1981-01       Impact factor: 4.406

9.  Effects of indomethacin in premature infants with patent ductus arteriosus: results of a national collaborative study.

Authors:  W M Gersony; G J Peckham; R C Ellison; O S Miettinen; A S Nadas
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

10.  Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus.

Authors:  H W Seyberth; W Rascher; R Hackenthal; L Wille
Journal:  J Pediatr       Date:  1983-12       Impact factor: 4.406

View more
  1 in total

Review 1.  Arachidonic acid metabolites and haemodynamics of the neonate.

Authors:  J L Reyes
Journal:  Pediatr Nephrol       Date:  1993-12       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.